Diabetes Therapy
Avandamet is combined metformin-rosiglitazone for type 2 diabetes therapy
Published in Obesity and Diabetes Week, January 10th, 2005
According to a study from England, "Insulin resistance is a major endocrinopathy underlying the development of hyperglycemia and cardiovascular disease in type 2 diabetes. Metformin (a biguanide) and rosiglitazone (a thiazolidinedione) counter insulin resistance, acting by different cellular mechanisms. The two agents can be used in combination to achieve additive glucose-lowering efficacy in the treatment of type 2 diabetes, without stimulating insulin secretion and without causing hypoglycemia. Both agents also reduce a range of atherothrombotic factors and markers,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Complications
Global risk management in type 2 diabetes reviewed - Diabetic Nephropathy
Dehydration in poorly controlled type 2 diabetes examined - Heart Disease Risk Factor
Postprandial glucose regulation and diabetic complications reviewed - Obesity and Diabetes
Insulin partners with leptin in hypothalamic control of energy homeostasis - Adipose Tissue
Changes in adipose tissue during weight loss described - Adipose Tissue
Fat mobilization in adipose tissue promoted by triglyceride lipase - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
